CRISPR Therapeutics AG lost $6.47 per diluted share in fiscal year 2025. This represents a decrease of 49.1% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $4.74 per diluted share. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters CRISPR Therapeutics AG has filed alongside them.
FY2025 annual
EPS (Diluted)-$6.47
YoY-49.1%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
CRSP EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was CRISPR Therapeutics AG's diluted earnings per share in fiscal year 2025?
CRISPR Therapeutics AG lost $6.47 per diluted share in fiscal year 2025.
How fast is CRISPR Therapeutics AG's diluted earnings per share growing?
CRISPR Therapeutics AG (CRSP) diluted earnings per share fell by 49.1% year over year, from -$4.34 to -$6.47 in fiscal year 2025.
What is CRISPR Therapeutics AG's diluted earnings per share over the last twelve months?
CRISPR Therapeutics AG (CRSP) reported a loss of $4.74 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was CRISPR Therapeutics AG's diluted earnings per share in the most recent quarter?
CRISPR Therapeutics AG (CRSP) reported -$0.94 in diluted earnings per share in Q2 2026. This represents an increase of 60.8% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what CRISPR Therapeutics AG (CRSP) reported on that line in every period on record.
